The applications of metabolomics in the molecular diagnostics of cancer

References

• Peng B, Li H, Peng -X-X. Functional metabolomics: from biomarker discovery to metabolome reprogramming. Protein Cell. 2015;6(9):628–637.
   PubMed Web of Science ®Google Scholar
• Xu XH, Huang Y, Wang G, et al. Metabolomics: a novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer’s disease. Neurosci Bull. 2012;28(5):641–648.
   PubMed Web of Science ®Google Scholar
• Marshall DD, Powers R. Beyond the paradigm: Combining mass spectrometry and nuclear magnetic resonance for metabolomics. Prog Nucl Magn Reson Spectrosc. 2017;100:1–16.
   PubMed Web of Science ®Google Scholar
• Commisso M, Strazzer P, Toffali K, et al. Untargeted metabolomics: an emerging approach to determine the composition of herbal products. Comput Struct Biotechnol J. 2013;4:e201301007.
   PubMedGoogle Scholar
• Vignoli A, Ghini V, Meoni G, et al. High-throughput metabolomics by 1D NMR. Angew Chem Int Ed Engl. 2019;58(4):968–994.
   PubMed Web of Science ®Google Scholar
• Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res. 2009;15(2):431–440.
   PubMed Web of Science ®Google Scholar
• Armitage EG, Barbas C. Metabolomics in cancer biomarker discovery: Current trends and future perspectives. J Pharm Biomed Anal. 2014;87:1–11.
   PubMed Web of Science ®Google Scholar
• Gowda GA, Djukovic D. Overview of mass spectrometry-based metabolomics: opportunities and challenges. Methods Mol Biol. 2014;1198:3–12.
   PubMedGoogle Scholar
• Armitage E, Kotze H, Lockyer N. Imaging of metabolites using secondary ion mass spectrometry. Metabolomics. 2013;9:102–109.
   Web of Science ®Google Scholar
• Kapoore RV, Vaidyanathan S. Towards quantitative mass spectrometry-based metabolomics in microbial and mammalian systems. Philos Trans A Math Phys Eng Sci. 2016;374:2079.
   Web of Science ®Google Scholar
• Dona AC, Kyriakides M, Scott F, et al. A guide to the identification of metabolites in NMR-based metabonomics/metabolomics experiments. Comput Struct Biotechnol J. 2016;14:135–153.
   PubMed Web of Science ®Google Scholar
• Mlynárik V. Introduction to nuclear magnetic resonance. Anal Biochem. 2017;529:4–9.
   PubMed Web of Science ®Google Scholar
• Li T, Deng P. Nuclear Magnetic Resonance technique in tumor metabolism. Genes Dis. 2017;4(1):28–36.
   PubMed Web of Science ®Google Scholar
• Bujak R, Struck-Lewicka W, Markuszewski MJ, et al. Metabolomics for laboratory diagnostics. J Pharm Biomed Anal. 2015;113:108–120.
   PubMed Web of Science ®Google Scholar
• Li J, Vosegaard T, Guo Z. Applications of nuclear magnetic resonance in lipid analyses: An emerging powerful tool for lipidomics studies. Prog Lipid Res. 2017;68:37–56.
   PubMed Web of Science ®Google Scholar
• Worley B, Powers R. Multivariate analysis in metabolomics. Curr Metabolomics. 2013;1(1):92–107.
   PubMedGoogle Scholar
• Deidda M, Piras C, Bassareo PP, et al. Metabolomics, a promising approach to translational research in cardiology. IJC Metab Endocr. 2015;9:31–38.
   Google Scholar
• Madsen R, Lundstedt T, Trygg J. Chemometrics in metabolomics - a review in human disease diagnosis. Anal Chim Acta. 2010;659(1–2):23–33.
   PubMed Web of Science ®Google Scholar
• Hospital Authority: Hong Kong Cancer Registry web site. [updated Apr 2019]. Available from: http://www3.ha.org.hk/cancereg/default.asp
   Google Scholar
• Bray F, Ferlay J, Soerjomataram L, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Jimenez B, Mirnezami R, Kinross J, et al. 1H HR-MAS NMR spectroscopy of tumor-induced local metabolic “field-effects” enables colorectal cancer staging and prognostication. J Proteome Res. 2013;12(2):959–968.
   PubMed Web of Science ®Google Scholar
• Fuss TL, Cheng LL. Evaluation of Cancer Metabolomics Using ex vivo High Resolution Magic Angle Spinning (HRMAS) Magnetic Resonance Spectroscopy (MRS). Metabolites. 2016;6(1):11.
   PubMed Web of Science ®Google Scholar
• Holst S, Stavenhagen K, Balog CI, et al. Investigations on aberrant glycosylation of glycosphingolipids in colorectal cancer tissues using liquid chromatography and matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF-MS). Mol Cell Proteomics. 2013;12(11):3081–3093.
   PubMed Web of Science ®Google Scholar
• Tan B, Qiu Y, Zou X, et al. Metabonomics identifies serum metabolite markers of colorectal cancer. J Proteome Res. 2013;12(6):3000–3009.
   PubMed Web of Science ®Google Scholar
• Leichtle AB, Nuoffer J-M, Ceglarek U, et al. Serum amino acid profiles and their alterations in colorectal cancer. Metabolomics. 2012;8(4):643–653.
   PubMed Web of Science ®Google Scholar
• Ritchie SA, Ahiahonu PW, Jayasinghe D, et al. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010;8:13.
   PubMed Web of Science ®Google Scholar
• Phua LC, Chue XP, Koh PK, et al. Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014;15(4):389–397.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Xie G, Chen T, et al. Distinct Urinary Metabolic Profile of Human Colorectal Cancer. J Proteome Res. 2012;11(2):1354–1363.
   PubMed Web of Science ®Google Scholar
• Chan EC, Koh PK, Mal M, et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res. 2009;8(1):352–361.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Cai G, Su M, et al. Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009;8(10):4844–4850.
   PubMed Web of Science ®Google Scholar
• Lima AR, Bastos Mde L, Carvalho M, et al. Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies. Transl Oncol. 2016;9(4):357–370.
   PubMed Web of Science ®Google Scholar
• Kelly RS, Vander Heiden MG, Giovannucci E, et al. Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence. Cancer Epidemiol Biomarkers Prev. 2016;25(6):887–906.
   PubMed Web of Science ®Google Scholar
• Shao Y, Ye G, Ren S, et al. Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer. Int J Cancer. 2018;143(2):396–407.
   PubMed Web of Science ®Google Scholar
• Khan N, Mukhtar H. Modulation of signaling pathways in prostate cancer by green tea polyphenols. Biochem Pharmacol. 2013;85(5):667–672.
   PubMed Web of Science ®Google Scholar
• Kim JU, Shariff MIF, Crossey MME, et al. Hepatocellular carcinoma: Review of disease and tumor biomarkers. World J Hepatol. 2016;8(10):471–484.
   PubMed Web of Science ®Google Scholar
• Beyoglu D, Idle JR. The metabolomic window into hepatobiliary disease. J Hepatol. 2013;59(4):842–858.
   PubMed Web of Science ®Google Scholar
• Wei S, Liu L, Zhang J, et al. Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol Oncol. 2013;7(3):297–307.
   PubMed Web of Science ®Google Scholar
• Hadi NI, Jamal Q, Iqbal A, et al. Serum metabolomic profiles for breast cancer diagnosis, grading and staging by gas chromatography-mass spectrometry. Sci Rep. 2017;7(1):1715.
   PubMedGoogle Scholar
• Budczies J, Denkert C. Tissue-based metabolomics to analyze the breast cancer metabolome. Recent Results Cancer Res. 2016;207:157–175.
   PubMedGoogle Scholar
• Budczies J, Denkert C, Müller BM, et al. Abstract 5573: GC-TOF mass spectroscopy reveals strong dependence of breast cancer metabolome on estrogene receptor, but not on HER2 status. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5573.
   Google Scholar
• Lefort N, Brown A, Lloyd V, et al. (1)H NMR metabolomics analysis of the effect of dichloroacetate and allopurinol on breast cancers. J Pharm Biomed Anal. 2014;93:77–85.
   PubMed Web of Science ®Google Scholar
• Hart CD, Vignoli A, Tenori L, et al. Serum metabolomic profiles identify ER-positive early breast cancer at increased risk of disease recurrence in a multicenter population. Clin Cancer Res. 2017;23(6):1422–1431.
   PubMed Web of Science ®Google Scholar
• Tenori L, Oakman C, Morris PG, et al. Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. Mol Oncol. 2015;9(1):128–139.
   PubMed Web of Science ®Google Scholar
• Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell. 2008;134(5):714–717.
   PubMed Web of Science ®Google Scholar
• Gao L, Wen Z, Wu C, et al. Metabolic profiling of plasma from benign and malignant pulmonary nodules patients using mass spectrometry-based metabolomics. Metabolites. 2013;3(3):539–551.
   PubMedGoogle Scholar